Regulatory Briefs: FDA Device Reclassifications, Meetings Announcements
This article was originally published in The Gray Sheet
Executive Summary
FDA proposes class II for nonthermal shortwave therapy devices and updates regulations to reflect class II designation for neuropsychiatric assessment device. Meetings on manufacturing quality, clinical trials and medical countermeasures announced. More regulatory news.
You may also be interested in...
Regulatory Briefs: Microbiology Panel Meeting; Advisory Committee Nomination Portal
FDA’s Microbiology Devices Panel advisory committee will vote on Roche’s cobas HPV Test as a first-line screening test. The agency launched an advisory committee nomination portal and sought nominations for certain device advisory panels. More regulatory news.
New Product Briefs: St. Jude TAVR Update; ADHD, GI Tests Launch
St. Jude expects to receive a CE mark for a transfemoral 25 millimeter version of its Portico transcatheter aortic valve replacement system during the fourth quarter. NEBA Health launches ADHD test. Exalenz BioScience launches test for H. pylori stomach bacteria.
Clinical Studies Needed For Nonthermal Shortwave Diathermy Devices, FDA Panel Says
The Orthopaedic and Rehabilitation Advisory Panel recommended FDA require a randomized, sham-control study design with a well-defined patient population to prove safety and effectiveness for the devices. The agency is currently considering whether to retain the preamendments device category in class III or downclassify to class II.